300
Participants
Start Date
June 1, 2012
Primary Completion Date
May 11, 2018
Study Completion Date
May 11, 2018
Evolocumab
Evolocumab was administered by subcutaneous injection either once a month (QM) or once every two weeks (Q2W).
Research Site, Brussels
Research Site, Johannesburg
Research Site, Perth
Research Site, Hobart
Research Site, La Louvière
Research Site, Observatory
Research Site, Christchurch
Research Site, New York
Research Site, New York
Research Site, New York
Research Site, Córdoba
Research Site, A Coruña
Research Site, Athens
Research Site, Cinisello Balsamo (MI)
Research Site, Dijon
Research Site, Lugo
Research Site, Madrid
Research Site, Nashville
Research Site, Cincinnati
Research Site, Ramat Gan
Research Site, Pisa
Research Site, Paris
Research Site, Napoli
Research Site, Los Angeles
Research Site, São Paulo
Research Site, São Paulo
Research Site, London
Research Site, Chicoutimi
Research Site, Montreal
Research Site, Montreal
Research Site, Québec
Research Site, Brno
Research Site, Hradec Králové
Research Site, Olomouc
Research Site, Prague
Research Site, Uherské Hradiště
Research Site, New Territories
Research Site, Kanazawa
Research Site, Suita
Research Site, Beirut
Research Site, Amsterdam
Research Site, Rotterdam
Research Site, Barcelona
Research Site, Manchester
Lead Sponsor
Amgen
INDUSTRY